251 results on '"DAR, PE'ER"'
Search Results
2. First-trimester screening for placenta accreta spectrum
3. Risk of endometrial polyp and surgical intervention in postmenopausal women with proliferative endometrium
4. Performance of prenatal cfDNA screening for sex chromosomes
5. Prenatal Screening for Microdeletions and Rare Autosomal Aneuploidies
6. The role of cell-free DNA biomarkers and patient data in the early prediction of preeclampsia: an artificial intelligence model
7. Obstetrical, Perinatal, and Genetic Outcomes Associated With Nonreportable Prenatal Cell-Free DNA Screening Results
8. The Role of cfDNA Biomarkers and Patient Data in the Early Prediction of Preeclampsia: Artificial Intelligence Model
9. Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results
10. Association of Intrauterine Device Malposition With Previous Cesarean Delivery and Related Uterine Anatomical Changes.
11. Early prediction of placenta accreta spectrum in women with prior cesarean delivery using transvaginal ultrasound at 11 to 14 weeks
12. 1190 Presence of SSA/SSB antibodies and risk of preeclampsia in patients with autoimmune disease
13. 291 Association of resolving placenta previa and other early sonographic markers with postpartum hemorrhage
14. 573 Does the addition of MRI in antenatal management of suspected PAS impact maternal surgical outcome?
15. 417 Does the allowable blood loss calculator predict postpartum blood transfusion?
16. 653 Timing of antenatal placenta accreta spectrum diagnosis and impact on clinical outcomes: a multicenter study
17. 614 Childhood Opportunity Index and Severe Morbidity in a cohort complicated by Placenta Accreta Spectrum Disorder
18. 1099 Placenta accreta spectrum (PAS) diagnosis timing and its effect on maternal and neonatal outcomes
19. 165 Machine learning for the prediction of surgical morbidity in placenta accreta spectrum
20. 659 Yield of serial prenatal ultrasounds for detection of congenital heart block in SSA/SSB antibody-positive patients
21. Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study
22. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation
23. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome
24. Non-reportable cell free DNA results in high-risk versus low-risk patients
25. Obstetrical, perinatal and genetic outcomes associated with non-reportable prenatal cell free DNA screening results
26. Association between transvaginal cerclage suture type and pregnancy outcomes
27. P636: Prenatal diagnosis of 7q, Xq/Yq deletion mosaicism in an alobar holoprosencephaly fetus: A case report and review of the literature
28. High fetal fraction on cell-free fetal DNA screening: is it associated with adverse perinatal outcomes?
29. Evaluating Expanded Noninvasive Prenatal Screening
30. Multicentre Prospective Study of SNP-Based cfDNA Screening for Aneuploidy with Genetic Confirmation in 18 497 Pregnancies
31. Colour Doppler ultrasound of spiral artery blood flow in the prediction of pre-eclampsia and intrauterine growth restriction
32. Performance of noninvasive prenatal screening for 22q11.2 deletion syndrome in the SMART study
33. Primary cell-free DNA screening or contingent screening for the common trisomies
34. Impact of introducing cell‐free DNA screening into clinical care on first trimester ultrasound
35. Immediate versus delayed cerclage removal following preterm prelabor rupture of membranes
36. Utility of cervical length measurement following a second trimester non-elective cerclage
37. Impact of race, insurance and income on diagnosis and outcomes of women with placenta accreta
38. cfDNA prenatal screening for Cri-Du-Chat, Prader-Willi/Angelman and 1p36del syndromes in 10,971 pregnancies with genetic confirmation
39. Positive predictive values and false-positive results in noninvasive prenatal screening
40. Nonreportable cell free DNA results in high-risk vs low-risk patients
41. 11 - Perinatal Ultrasound
42. Performance of ultrasound, maternal serum screening and cell-free DNA for the detection of 22q11.2 deletion syndrome
43. Prenatal genetic screening and diagnostic testing during the COVID-19 pandemic in the Bronx, NY
44. 67 Multicenter prospective study of SNP-based cfDNA for 22q11.2 deletion in 18,289 pregnancies with genetic confirmation
45. 62 Multicenter prospective study of SNP-based cfDNA screening for aneuploidy with genetic confirmation in 18,496 pregnancies
46. 931 Maternal and neonatal outcomes associated with vasa previa resolution during the antepartum period
47. 5 Perinatal and genetic outcomes associated with no call cfDNA results in 18,496 pregnancies
48. Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling
49. Risk of Cancer and Performance of Ultrasound in Postmenopausal Women Who Failed Endometrial Biopsy [36R]
50. The Performance of Endometrial Biopsy and Transvaginal Sonogram in Endometrial Polyp Diagnosis [12Q]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.